VANI is the ticker symbol for Vivani Medical, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks VANI with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is VANI a good stock to buy?

VANI is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/VANI.

Where does 13F Pro source VANI data?

All Vivani Medical, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vivani Medical, Inc. files with the SEC under CIK 1266806. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Vivani Medical, Inc.(VANI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Vivani Medical, Inc. (VANI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VANI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $8.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Vivani Medical, Inc. reports net income of $-6.4M, free cash flow of $-6.1M. Top institutional holders of VANI by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Tanager Wealth Management LLP, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VANI trades on the Nasdaq exchange and files with the SEC under CIK 1266806. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VANI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vivani Medical, Inc. directly from SEC EDGAR.

Net Income

$-6.4M

Free Cash Flow

$-6.1M

VANI key financials by period

Vivani Medical, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2019	10-K	$3.4M	$-33.6M	—
FY 2018	10-K	$6.9M	$-35.1M	—
FY 2017	10-K	$8.0M	$-28.5M	—
FY 2016	10-K	$4.0M	$-33.2M	—
FY 2015	10-K	$8.9M	$-20.0M	—
FY 2014	10-K	$3.4M	$-35.2M	—

Institutions holding VANI

Institutional investors reporting a position in Vivani Medical, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
VANGUARD CAPITAL MANAGEMENT	1,768,077	$2.2M	2026-06-30
Tanager Wealth Management LLP	607,276	$753.0K	2026-06-30
GEODE CAPITAL MANAGEMENT	587,745	$728.9K	2026-06-30
TUDOR INVESTMENT ET AL	410,902	$509.5K	2026-06-30
COMMONWEALTH EQUITY SERVICES	330,565	$409.9K	2026-06-30
VANGUARD FIDUCIARY	325,462	$403.6K	2026-06-30
BlackRock	301,828	$374.3K	2026-06-30
MONETARY MANAGEMENT GROUP	193,977	$240.5K	2026-06-30
STATE STREET	154,965	$192.2K	2026-06-30
NORTHERN	116,907	$145.0K	2026-06-30

SEC EDGAR: CIK 1266806 →

Vivani Medical, Inc.

VANI

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $8.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.